| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/04/2001 | WO2001000869A2 Arrays of catalytic or pre-catalytic nucleic acids |
| 01/04/2001 | WO2001000864A2 Nucleic acid binding of multi-zinc finger transcription factors |
| 01/04/2001 | WO2001000860A2 Prolactin-inducible mammary specific promoter |
| 01/04/2001 | WO2001000859A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | WO2001000837A1 Basb111 polypeptide and polynucleotide from moraxella catharrhalis |
| 01/04/2001 | WO2001000835A1 Moraxella catarrhalis polypeptides |
| 01/04/2001 | WO2001000830A1 Sgip peptides |
| 01/04/2001 | WO2001000829A2 Human endogenous retrovirus in breast cancer |
| 01/04/2001 | WO2001000824A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 01/04/2001 | WO2001000822A2 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 01/04/2001 | WO2001000821A1 Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof |
| 01/04/2001 | WO2001000818A1 Gene encoding promoter domain of tumor suppressor gene p51 and use thereof |
| 01/04/2001 | WO2001000809A1 Self-induced deletion of dna |
| 01/04/2001 | WO2001000808A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | WO2001000791A1 Stress-responsive induction of a therapeutic agent and methods of use |
| 01/04/2001 | WO2001000784A2 Compound derived from an offset orf of the ice gene |
| 01/04/2001 | WO2001000709A1 Copolymers for the transfer of nucleic acids to the cell |
| 01/04/2001 | WO2001000708A1 Combinations for introducing nucleic acids into cells |
| 01/04/2001 | WO2001000664A2 Secreted alpha-helical protein-36 |
| 01/04/2001 | WO2001000662A2 The use of human fgh-8 polypeptides as neurotrophic agents |
| 01/04/2001 | WO2001000650A1 Cytoplasmic transfer to de-differentiate recipient cells |
| 01/04/2001 | WO2001000645A1 Antisense modulation of integrin beta 3 expression |
| 01/04/2001 | WO2001000247A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | WO2001000241A2 Novel vector complexes and their use in gene therapy |
| 01/04/2001 | WO2001000228A1 Method for preventing tumoral growth |
| 01/04/2001 | WO2001000220A2 Lipoprotein lipase (lpl) variant therapeutics |
| 01/04/2001 | WO2001000031A1 Stem cells derived from skeletal muscle |
| 01/04/2001 | WO2000064400A3 Methods for treating congestive heart failure |
| 01/04/2001 | WO2000062798A3 Angiogenic growth factors for treatment of peripheral neuropathy |
| 01/04/2001 | WO2000058501A3 Novel genetic suppressor elements and methods of making the same |
| 01/04/2001 | WO2000058455A3 Methods for the identification and validation of functional intracellular targets with intramers or in vivo selection |
| 01/04/2001 | WO2000057921A3 Peroral gene therapy of diabetes and obesity |
| 01/04/2001 | WO2000057917A3 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 01/04/2001 | WO2000056405A3 Human tumor necrosis factor receptor-like 2 |
| 01/04/2001 | WO2000047235A3 Methods of stimulating angiogenesis |
| 01/04/2001 | WO2000039302A3 Improved expression of hiv polypeptides and production of virus-like particles |
| 01/04/2001 | WO2000029438A9 Egf-like nucleic acids and polypeptides and uses thereof |
| 01/04/2001 | CA2435411A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | CA2415095A1 Secreted alpha-helical protein-36 |
| 01/04/2001 | CA2378227A1 Antisense modulation of pi3k p85 expression |
| 01/04/2001 | CA2378221A1 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype |
| 01/04/2001 | CA2377721A1 Sgip peptides |
| 01/04/2001 | CA2377541A1 Method of inducing angiogenesis by micro-organs |
| 01/04/2001 | CA2377531A1 Basb111 polypeptide and polynucleotide from moraxella catarrhalis |
| 01/04/2001 | CA2377515A1 Cytoplasmic transfer to de-differentiate recipient cells |
| 01/04/2001 | CA2377462A1 Moraxella catarrhalis polypeptides |
| 01/04/2001 | CA2377438A1 Gene encoding promoter domain of tumor suppressor gene p51 and use thereof |
| 01/04/2001 | CA2377437A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | CA2377434A1 Stress-responsive induction of a therapeutic agent and methods of use |
| 01/04/2001 | CA2377433A1 Compound derived from an offset orf of the ice gene |
| 01/04/2001 | CA2377273A1 Antisense oligonucleotide modulating cyclin e gene expression and therapeutic uses thereof |
| 01/04/2001 | CA2377211A1 Copolymers for transporting nucleic acids in the cell |
| 01/04/2001 | CA2377207A1 Combinations for introducing nucleic acids into cells |
| 01/04/2001 | CA2376920A1 Method for preventing tumoral growth |
| 01/04/2001 | CA2376859A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | CA2370687A1 Nucleic acid binding of multi-zinc finger transcription factors |
| 01/04/2001 | CA2370081A1 Lpl variant therapeutics |
| 01/03/2001 | EP1065270A1 HUMAN p51 GENES AND GENE PRODUCTS THEREOF |
| 01/03/2001 | EP1064952A2 Methods and compositions for the suppression of neu mediated transformations |
| 01/03/2001 | EP1064404A1 P53-regulated genes |
| 01/03/2001 | EP1064403A1 Antisense modulation of pecam-1 |
| 01/03/2001 | EP1064402A1 Antisense modulation of lfa-3 |
| 01/03/2001 | EP1064392A2 Multigene vectors |
| 01/03/2001 | EP1064391A1 Antisense modulation of human mdm2 expression |
| 01/03/2001 | EP1064390A1 Enhanced anti-tumor immunity |
| 01/03/2001 | EP1064383A2 Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| 01/03/2001 | EP1064380A1 EXPRESSION OF THE $i(INSL4) GENE IN HUMAN EMBRYONIC BONE TISSUES AND APPLICATIONS |
| 01/03/2001 | EP1064379A2 Human nucleic acid sequences from tissue of breast tumors |
| 01/03/2001 | EP1064378A2 Hypoxia-inducible human genes, proteins, and uses thereof |
| 01/03/2001 | EP1064374A1 Novel molecules expressed during muscle development and genetic sequences encoding the same |
| 01/03/2001 | EP1064372A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/03/2001 | EP1064371A2 Isolated mammalian membrane protein genes and related reagents |
| 01/03/2001 | EP1064366A1 $i(STAPHYLOCOCCUS AUREUS) GENES AND POLYPEPTIDES |
| 01/03/2001 | EP1064363A1 Retroviral packaging cell line |
| 01/03/2001 | EP1064354A1 Compositions and methods for gene-based vaccines to provoke t cell responses |
| 01/03/2001 | EP1064306A1 $i(NEPHRIN) GENE AND PROTEIN |
| 01/03/2001 | EP1064297A1 95 human secreted proteins |
| 01/03/2001 | EP1064026A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 01/03/2001 | EP1064020A1 Methods for diagnosing and treating autoimmune disease |
| 01/03/2001 | EP1064007A1 nrdG |
| 01/03/2001 | EP1063997A2 Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 01/03/2001 | EP1063891A2 Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby |
| 01/03/2001 | EP0807183B1 Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle |
| 01/03/2001 | CN1278865A Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
| 01/03/2001 | CN1278864A Genetically modified tumor-targeted bacteria with reduced virulence |
| 01/03/2001 | CN1278739A Method of delivering genes to antigen presenting cells of the skin |
| 01/03/2001 | CN1278736A Hmanized antibodies to human gp39, compositions containing and therapeutic use thereof |
| 01/03/2001 | CN1060177C 3'-monophosphorylated oligonucleotides |
| 01/02/2001 | US6169079 An antisense oligonucleotides designed to hybridize to the mrna encoding intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, for treating inflammation |
| 01/02/2001 | US6169078 Materials and methods for the intracellular delivery of substances |
| 01/02/2001 | US6168953 Increasing efficiency of viricide in host cell by contacting with vector derived from spumavirinae, spumavirus, lentivirinae, or lentivirus; vector contains a cis-acting genetic element which colocalizes the viricide with target |
| 01/02/2001 | US6168950 Compound 8 to 30 nucleotides in length which specifically hybridizes and inhibits gene expression of human mitogen-activated protein kinase kinase kinase 1; anticarcinogenic/antiproliferative agents |
| 01/02/2001 | US6168946 gp75 as a tumor vaccine for melanoma |
| 01/02/2001 | US6168942 Attenuated forms of bovine viral diarrhea virus |
| 01/02/2001 | US6168933 Nucleotide sequences coding a transport protein; for the classification, diagnosis, prevention, and treatment of defects in cell proliferation, lipid metabolism and transport |
| 01/02/2001 | US6168916 Host adaptation of retroviral vectors |
| 01/02/2001 | US6168787 Pluripotent vaccine against enveloped viruses |
| 01/02/2001 | US6167888 Method for inducing partial recovery of lost voluntary motor function after spinal cord injury in a mammal |
| 12/28/2000 | WO2000079281A1 Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer |
| 12/28/2000 | WO2000078987A1 Vector for expressing two foreign genes |